GlassScriptPhysician profile
Adhirath Doshi
NPI 1992110753
$10,499.85
in general payments reported to CMS, 2019-2025
36 companies · $2,125 in 2025
The $2,125 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,843 · 2020: $561 · 2021: $220 · 2022: $490 · 2023: $468 · 2024: $4,792 · 2025: $2,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,293 · Travel and Lodging: $3,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,292.71 |
| Travel and Lodging | $3,092.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,843.00 | 2023-2025 | Advisa Dr Mri Surescan, Mycarelink, Attesta Sr Mri Surescan |
| Heartflow, INC. | $1,342.00 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $678.08 | 2019-2025 | |
| Baxter Healthcare | $565.89 | 2022-2025 | Hillrom - Carnation Ambulatory Monitor |
| Astrazeneca Pharmaceuticals LP | $487.49 | 2019-2025 | Farxiga, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $406.41 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $362.23 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $276.75 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $267.44 | 2019-2024 | Lifevest |
| Amgen INC. | $222.16 | 2020-2025 | Repatha, Repatha |
| Welch Allyn | $220.40 | 2021 | |
| Boston Scientific Corporation | $187.49 | 2023-2025 | Ekosonic, Lux-Dx Insertable Cardiac Monitor, General - Pain Management |
| Medtronic Vascular, INC. | $172.32 | 2019-2020 | |
| Abbott Laboratories | $163.51 | 2019-2025 | Cardiomems, Aveir |
| Pfizer INC. | $153.24 | 2019-2025 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adhirath Doshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.